Barclays Initiates Coverage on BioCryst Pharmaceuticals (BCRX)

Equities research analysts at Barclays initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report released on Wednesday. The brokerage set an “equal weight” rating and a $6.00 price target on the biotechnology company’s stock. Barclays’ target price would suggest a potential upside of 20.00% from the company’s previous close.

A number of other equities research analysts also recently weighed in on BCRX. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. ValuEngine raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $15.00 price objective (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, September 5th. J P Morgan Chase & Co raised shares of BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $6.00 to $9.00 in a research note on Tuesday, September 5th. Finally, Jefferies Group raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $5.00 to $7.00 in a research note on Wednesday, September 6th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $8.63.

Shares of BioCryst Pharmaceuticals (NASDAQ BCRX) opened at $5.00 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.53 and a current ratio of 2.53. BioCryst Pharmaceuticals has a 1 year low of $3.95 and a 1 year high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). BioCryst Pharmaceuticals had a negative net margin of 167.58% and a negative return on equity of 123.16%. The business had revenue of $8.76 million during the quarter, compared to the consensus estimate of $5.05 million. During the same quarter in the prior year, the firm earned ($0.16) EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 64,310 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $4.72, for a total transaction of $303,543.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.80% of the company’s stock.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 19.9% in the 2nd quarter. Vanguard Group Inc. now owns 6,007,815 shares of the biotechnology company’s stock worth $33,404,000 after acquiring an additional 996,052 shares during the period. RA Capital Management LLC lifted its stake in shares of BioCryst Pharmaceuticals by 47.9% in the 2nd quarter. RA Capital Management LLC now owns 5,162,242 shares of the biotechnology company’s stock worth $28,702,000 after acquiring an additional 1,672,447 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter worth approximately $23,762,000. State Street Corp lifted its stake in shares of BioCryst Pharmaceuticals by 72.0% in the 2nd quarter. State Street Corp now owns 3,909,013 shares of the biotechnology company’s stock worth $21,736,000 after acquiring an additional 1,636,909 shares during the period. Finally, VHCP Management II LLC lifted its stake in shares of BioCryst Pharmaceuticals by 27.9% in the 3rd quarter. VHCP Management II LLC now owns 3,165,457 shares of the biotechnology company’s stock worth $16,587,000 after acquiring an additional 690,290 shares during the period. 84.69% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/22/barclays-initiates-coverage-on-biocryst-pharmaceuticals-bcrx.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

What are top analysts saying about BioCryst Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioCryst Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit